DEA-Licensed Marijuana Grower Launches Contract Research Organization

Maridose, a DEA-licensed cannabis grower launched a Contract Research Organization (CRO) group dedicated to collaborations with researchers engaged in the development of cannabis-based drugs for pre-clinical and clinical trials, as well as aiding in the commercialization process.

The company noted that its new CRO services cater to pharmaceutical and biotech firms, academic institutions, authorized cannabis companies as well as other entities legally permitted to research Schedule I drugs. Furthermore, the group will provide a comprehensive suite of offerings designed to support every phase of drug development, from initial research to final commercialization. Services include but are not limited to:

• Pre-clinical and clinical trial support: Providing expertise in the design, execution, and monitoring of pre-clinical and clinical trials for cannabis-derived pharmaceuticals.

• Regulatory guidance: Assisting clients in navigating the complex regulatory landscape, including advice on obtaining necessary licenses for conducting research on Schedule I substances.

• Formulation development: Collaborating with researchers to optimize drug formulations for enhanced efficacy and safety.

• Quality control and assurance: Implementing rigorous quality control measures to ensure compliance with industry standards and regulatory requirements.

"As the only DEA-licensed manufacturer providing comprehensive CRO services, the launch of our CRO group marks a significant milestone for the research community,” Maridose's CEO Lisa Rich-Milan stated. “We are dedicated to fostering advancements in cannabis-based medicine and are committed to supporting researchers and organizations striving to make breakthroughs in this rapidly evolving field."

Related Links: World-Renowned Cannabis Researcher, Professor Lumir Hanus, Joins DEA-Licensed Schedule 1 Drug Manufacturer Maridose

Photo: Courtesy of  Aphiwat chuangchoem via Pexels